Targeting cancer with a lupus autoantibody

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Systemic lupus erythematosus (SLE) is characterized by autoantibodies against host DNA.
• The role of anti-DNA antibodies in SLE pathogenesis is unclear.
• Lupus autoantibodies have not been explored for cancer therapy.

Purpose of the Study:

• To investigate the potential of a lupus autoantibody, 3E10, as a targeted cancer therapy.
• To explore 3E10's mechanism of action in DNA repair and its effect on cancer cells.

Main Methods:

• Assessed 3E10 binding to DNA single-strand tails.
• Evaluated 3E10's inhibition of DNA single-strand and double-strand break repair.
• Tested 3E10's efficacy in sensitizing cultured tumor cells and xenografts to DNA-damaging agents (doxorubicin, radiation).
• Determined 3E10's synthetic lethality in BRCA2-deficient cancer cells.

Main Results:

• 3E10 preferentially binds DNA single-strand tails.
• 3E10 inhibits key DNA repair pathways.
• 3E10 sensitizes tumor cells and xenografts to chemotherapy and radiation.
• 3E10 is synthetically lethal to BRCA2-deficient cancer cells, enhancing sensitivity to doxorubicin.

Conclusions:

• The lupus autoantibody 3E10 shows promise as a targeted therapy for DNA repair-deficient malignancies, particularly BRCA2-related cancers.
• Lupus autoantibodies may represent a source of novel therapeutic agents for cancer treatment.
• Findings suggest lupus autoantibodies might contribute to DNA repair deficiencies and cancer incidence in SLE patients.